Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SR34006 · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| SR34006 (idraparinux sodium) Injection | DRUG | - |
| vitamin K antagonist (warfarin or acenocoumarol) tablets | DRUG | - |
| SR34006 | DRUG | - |
| (LMW)heparin | DRUG | - |
| Warfarin VKA | DRUG | - |
| Acenocoumarol VKA | DRUG | - |
Inclusion Criteria: * Patients with confirmed symptomatic Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT) who have been treated with acenocoumarol, warfarin or SR34006 for six months * Written informed consent Exclusion Criteria: * Legal age limitations (country specific) * Indication for a...
SR34006 is an investigational small molecule being developed for cardiovascular conditions, specifically atrial fibrillation and pulmonary embolism. It has been studied in Phase 3 clinical trials for these indications, including use in patients who have completed treatment for symptomatic pulmonary embolism or deep vein thrombosis.
SR34006 is being developed by Sanofi, a biopharmaceutical company traded on the stock exchange under the ticker symbol SNY. The drug has been evaluated in Phase 3 clinical trials for cardiovascular indications.
SR34006 has completed Phase 3 clinical trials. It is an investigational drug that has been studied in trials for atrial fibrillation and pulmonary embolism. The drug is not approved and remains in clinical development.
SR34006 has been studied in three completed Phase 3 trials: NCT00062803 compared it to vitamin K antagonist in pulmonary embolism treatment, NCT00070655 (AMADEUS) evaluated it against warfarin or acenocoumarol in atrial fibrillation patients, and NCT00071279 compared it to placebo after six months of treatment for symptomatic pulmonary embolism or deep vein thrombosis.
SR34006 is also known as idraparinux. It is a factor Xa inhibitor being developed by Sanofi for cardiovascular conditions. The drug has been studied in Phase 3 trials for atrial fibrillation and pulmonary embolism.